On the morning of Thursday, March 7, the House Ways & Means Committee’s Subcommittee on Health held a hearing titled Promoting Competition to Lower Medicare Drug Prices. The hearing focused a great deal on the effect of patents in the pharmaceutical industry as they relate to pricing. Although some of the Republican membership of the subcommittee pointed out issues with various proposals to limit patent protections for drugmakers, the panel acted largely as a firing squad for patents. In his closing statement, Rep. Doggett expressed his dissatisfaction with the tenor of the day’s debate. “I view it as encouraging that there is bipartisan recognition of the serious problems so many Americans are facing with, really, prescription price gouging,” he said. “The question is whether we’ll have any bipartisan agreement on doing anything about it.”
The post House Health Subcommittee Holds Fractious Hearing on Drug Pricing and Patent Protections appeared first on IPWatchdog.com | Patents & Patent Law.
Recent Posts
- Stewart Rejects Motorola’s Argument that Director Reviews Applied New Fintiv Guidance Retroactively
- Perlmutter Says Trump’s Attempt to Remove Her as Register is ‘Blatantly Unlawful’ and Has No Effect
- Brazil: Senate Advances Discussions on Bill to Regulate AI Use
- ITC Asks Federal Circuit to Redo Lashify Ruling on Domestic Industry Interpretation
- Squires Calls for ‘Born Strong’ Patents in Light of USPTO’s Dire ‘Defective’ Patent Rate